Androgen receptor and heterogeneous nuclear ribonucleoprotein K colocalize in the nucleoplasm and are modulated by bicalutamide and 4-hydroxy-tamoxifen in prostatic cancer cell lines-Reference-Cited by-同舟云学术

Androgen receptor and heterogeneous nuclear ribonucleoprotein K colocalize in the nucleoplasm and are modulated by bicalutamide and 4-hydroxy-tamoxifen in prostatic cancer cell lines

Published:2011-02-14 Issue:13 Volume:71 Page:1466-1479
ISSN:0270-4137
Container-title:The Prostate
language:en
Short-container-title:Prostate

Author:

Barboro Paola,Repaci Erica,Ferrari Nicoletta,Rubagotti Alessandra,Boccardo Francesco,Balbi Cecilia

Funder

Regione Liguria

Compagnia San Paolo

Ministero dell'Universita' e Ricerca Scientifica (MIUR) Project PRIN, Italy

Ministero della Salute

Publisher

Wiley

Subject

Urology,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/pros.21366/fullpdf

Reference49 articles.

1. Antiandrogens in the treatment of prostate cancer;Wirth;Eur Urol,2007

2. Management of gynaecomastia in patients with prostate cancer: A systematic review;Di Lorenzo;Lancet Oncol,2005

3. Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer;Boccardo;J Clin Oncol,2005

4. An open, randomised, multicentre, phase 3 trial comparing the efficacy of two tamoxifen schedules in preventing gynecomastia induced by bicalutamide monotherapy in prostate cancer patients;Bedognetti;Eur Urol,2010

5. Editorial comment on: Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150mg monotherapy in patients with prostate cancer: A randomised, placebo-controlled, dose-response study;Van Poppel;Eur Urol,2007

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PTBP1 Genetic Variants Affect the Clinical Response to Androgen-deprivation Therapy in Patients With Prostate Cancer;Cancer Genomics - Proteomics;2021

2. The role of actinin-4 (ACTN4) in exosomes as a potential novel therapeutic target in castration-resistant prostate cancer;Biochemical and Biophysical Research Communications;2020-03

3. A hnRNP K–AR-Related Signature Reflects Progression toward Castration-Resistant Prostate Cancer;International Journal of Molecular Sciences;2018-06-30

4. Adaptive phenotype drives resistance to androgen deprivation therapy in prostate cancer;Cell Communication and Signaling;2017-12

5. Heterogeneous nuclear ribonucleoprotein K upregulates the kinetochore complex component NUF2 and promotes the tumorigenicity of colon cancer cells;Biochemical and Biophysical Research Communications;2015-03